These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 17148582)

  • 1. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia.
    Scheinberg P; Fischer SH; Li L; Nunez O; Wu CO; Sloand EM; Cohen JI; Young NS; John Barrett A
    Blood; 2007 Apr; 109(8):3219-24. PubMed ID: 17148582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation and dynamics of cytomegalovirus and Epstein-Barr virus after rabbit antithymocyte globulin and cyclosporine for aplastic anemia.
    Park SS; Cho SY; Han E; Min GJ; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Cho SG; Lee JW
    Eur J Haematol; 2019 Oct; 103(4):433-441. PubMed ID: 31381187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab.
    Gill H; Hwang YY; Chan TS; Pang AW; Leung AY; Tse E; Kwong YL
    J Clin Virol; 2014 Apr; 59(4):255-8. PubMed ID: 24507802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for adult T cell leukemia.
    Ogata M; Satou T; Kawano R; Yoshikawa T; Ikewaki J; Kohno K; Ando T; Miyazaki Y; Ohtsuka E; Saburi Y; Kikuchi H; Saikawa T; Kadota J
    J Med Virol; 2011 Apr; 83(4):702-9. PubMed ID: 21328386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab.
    Cheung WW; Tse E; Leung AY; Yuen KY; Kwong YL
    Am J Hematol; 2007 Feb; 82(2):108-11. PubMed ID: 17013817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation.
    Zhou JR; Shi DY; Wei R; Wang Y; Yan CH; Zhang XH; Xu LP; Liu KY; Huang XJ; Sun YQ
    Front Immunol; 2020; 11():620891. PubMed ID: 33664733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
    O'Brien SM; Keating MJ; Mocarski ES
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
    G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia.
    Scheinberg P; Nunez O; Weinstein B; Scheinberg P; Wu CO; Young NS
    Blood; 2012 Jan; 119(2):345-54. PubMed ID: 22067384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia.
    Calistri E; Tiribelli M; Battista M; Michelutti A; Corbellino M; Viale P; Fanin R; Damiani D
    Am J Hematol; 2006 May; 81(5):355-7. PubMed ID: 16628717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
    Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim SH; Kim HJ; Cho SG; Eom KS; Lee JW; Min WS; Shin WS; Kim CC
    Transpl Infect Dis; 2009 Oct; 11(5):413-23. PubMed ID: 19708893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies.
    Siegal D; Xu W; Sutherland R; Kamel-Reid S; Kuruvilla J; Lipton JH; Minden M; Messner H; Gupta V
    Bone Marrow Transplant; 2008 Jul; 42(1):51-6. PubMed ID: 18372907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.
    Carpenter B; Haque T; Dimopoulou M; Atkinson C; Roughton M; Grace S; Denovan S; Fielding A; Kottaridis PD; Griffiths P; Mackinnon S; Emery V; Chakraverty R
    Transplantation; 2010 Sep; 90(5):564-70. PubMed ID: 20555307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
    Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
    Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No indication of increased infection rates using low-dose alemtuzumab instead of anti-thymocyte globulin as graft-versus-host disease prophylaxis before allogeneic stem cell transplantation.
    Neumann T; Schneidewind L; Thiele T; Pink D; Schulze M; Schmidt C; Krüger W
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29178248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Reactivation of Cytomegalovirus and Epstein-Barr Virus in Patients with B Cell Lymphoma.
    Hatayama Y; Watanabe K; Ichikawa H; Kawamura K; Fukuda T; Motokura T
    Viral Immunol; 2023 Oct; 36(8):520-525. PubMed ID: 37440168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Epstein-Barr virus-associated leukemic lymphoma in a patient treated with rabbit antithymocyte globulin and cyclosporine for hepatitis-associated aplastic anemia.
    Ohata K; Iwaki N; Kotani T; Kondo Y; Yamazaki H; Nakao S
    Acta Haematol; 2012; 127(2):96-9. PubMed ID: 22178718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
    Ng AP; Worth L; Chen L; Seymour JF; Prince HM; Slavin M; Thursky K
    Haematologica; 2005 Dec; 90(12):1672-9. PubMed ID: 16330442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited predictive value of real-time quantitative PCR cytomegalovirus monitoring in the blood. Fatal CMV pneumonia in an autologous stem cell transplant recipient previously treated with alemtuzumab.
    Halaburda K; Nasiłowska-Adamska B; Grabarczyk P; Szczepiński A; Szpila T; Warzocha K; Mariańska B
    Ann Transplant; 2007; 12(2):37-40. PubMed ID: 18173065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
    Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
    J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.